Literature DB >> 28427814

Design, synthesis, and X-ray structural studies of BACE-1 inhibitors containing substituted 2-oxopiperazines as P1'-P2' ligands.

Arun K Ghosh1, Margherita Brindisi2, Yu-Chen Yen3, Emilio L Cárdenas2, Jean-Rene Ella-Menye2, Nagaswamy Kumaragurubaran2, Xiangping Huang4, Jordan Tang5, Andrew D Mesecar6.   

Abstract

We report the design and synthesis of a series of BACE1 inhibitors incorporating mono- and bicyclic 6-substituted 2-oxopiperazines as novel P1' and P2' ligands and isophthalamide derivative as P2-P3 ligands. Among mono-substituted 2-oxopiperazines, inhibitor 5a with N-benzyl-2-oxopiperazine and isophthalamide showed potent BACE1 inhibitory activity (Ki=2nM). Inhibitor 5g, with N-benzyl-2-oxopiperazine and substituted indole-derived P2-ligand showed a reduction in potency. The X-ray crystal structure of 5g-bound BACE1 was determined and used to design a set of disubstituted 2-oxopiperazines and bicyclic derivatives that were subsequently investigated. Inhibitor 6j with an oxazolidinone derivative showed a BACE1 inhibitory activity of 23nM and cellular EC50 of 80nM.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alzheimer’s disease; BACE-1; Memapsin 2; Protease inhibitors; β-Secretase

Mesh:

Substances:

Year:  2017        PMID: 28427814      PMCID: PMC5479133          DOI: 10.1016/j.bmcl.2017.04.011

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  27 in total

1.  Synthesis and diastereoselective reactions of n,n-dibenzylamino aldehydes and related compounds.

Authors:  M T Reetz
Journal:  Chem Rev       Date:  1999-05-12       Impact factor: 60.622

2.  Structure-based design of potent and selective cell-permeable inhibitors of human beta-secretase (BACE-1).

Authors:  Shawn J Stachel; Craig A Coburn; Thomas G Steele; Kristen G Jones; Elizabeth F Loutzenhiser; Alison R Gregro; Hemaka A Rajapakse; Ming-Tain Lai; Ming-Chih Crouthamel; Min Xu; Katherine Tugusheva; Janet E Lineberger; Beth L Pietrak; Amy S Espeseth; Xiao-Ping Shi; Elizabeth Chen-Dodson; M Katharine Holloway; Sanjeev Munshi; Adam J Simon; Lawrence Kuo; Joseph P Vacca
Journal:  J Med Chem       Date:  2004-12-16       Impact factor: 7.446

3.  Design, synthesis and X-ray structure of protein-ligand complexes: important insight into selectivity of memapsin 2 (beta-secretase) inhibitors.

Authors:  Arun K Ghosh; Nagaswamy Kumaragurubaran; Lin Hong; Hui Lei; Khaja Azhar Hussain; Chun-Feng Liu; Thippeswamy Devasamudram; Vajira Weerasena; Robert Turner; Gerald Koelsch; Geoffrey Bilcer; Jordan Tang
Journal:  J Am Chem Soc       Date:  2006-04-26       Impact factor: 15.419

4.  Design, synthesis, and X-ray structure of potent memapsin 2 (beta-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands.

Authors:  Arun K Ghosh; Nagaswamy Kumaragurubaran; Lin Hong; Sarang S Kulkarni; Xiaoming Xu; Wanpin Chang; Vajira Weerasena; Robert Turner; Gerald Koelsch; Geoffrey Bilcer; Jordan Tang
Journal:  J Med Chem       Date:  2007-04-14       Impact factor: 7.446

5.  Design, synthesis, and crystal structure of hydroxyethyl secondary amine-based peptidomimetic inhibitors of human beta-secretase.

Authors:  Michel C Maillard; Roy K Hom; Timothy E Benson; Joseph B Moon; Shumeye Mamo; Michael Bienkowski; Alfredo G Tomasselli; Danielle D Woods; D Bryan Prince; Donna J Paddock; Thomas L Emmons; John A Tucker; Michael S Dappen; Louis Brogley; Eugene D Thorsett; Nancy Jewett; Sukanto Sinha; Varghese John
Journal:  J Med Chem       Date:  2007-02-22       Impact factor: 7.446

Review 6.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

Review 7.  The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential.

Authors:  Robert Vassar; Dora M Kovacs; Riqiang Yan; Philip C Wong
Journal:  J Neurosci       Date:  2009-10-14       Impact factor: 6.167

8.  Rational design of novel, potent piperazinone and imidazolidinone BACE1 inhibitors.

Authors:  J N Cumming; T X Le; S Babu; C Carroll; X Chen; L Favreau; P Gaspari; T Guo; D W Hobbs; Y Huang; U Iserloh; M E Kennedy; R Kuvelkar; G Li; J Lowrie; N A McHugh; L Ozgur; J Pan; E M Parker; K Saionz; A W Stamford; C Strickland; D Tadesse; J Voigt; L Wang; Y Wu; L Zhang; Q Zhang
Journal:  Bioorg Med Chem Lett       Date:  2008-04-25       Impact factor: 2.823

9.  BACE1 inhibitor drugs in clinical trials for Alzheimer's disease.

Authors:  Robert Vassar
Journal:  Alzheimers Res Ther       Date:  2014-12-24       Impact factor: 6.982

Review 10.  Current concepts in Alzheimer's Disease: molecules, models and translational perspectives.

Authors:  Bart P F Rutten; Harry W M Steinbusch
Journal:  Mol Neurodegener       Date:  2013-10-22       Impact factor: 14.195

View more
  3 in total

Review 1.  A Close Look at BACE1 Inhibitors for Alzheimer's Disease Treatment.

Authors:  Brati Das; Riqiang Yan
Journal:  CNS Drugs       Date:  2019-03       Impact factor: 5.749

Review 2.  Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment.

Authors:  Judite R M Coimbra; Daniela F F Marques; Salete J Baptista; Cláudia M F Pereira; Paula I Moreira; Teresa C P Dinis; Armanda E Santos; Jorge A R Salvador
Journal:  Front Chem       Date:  2018-05-24       Impact factor: 5.221

Review 3.  BACE1 Function and Inhibition: Implications of Intervention in the Amyloid Pathway of Alzheimer's Disease Pathology.

Authors:  Gerald Koelsch
Journal:  Molecules       Date:  2017-10-13       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.